Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

HeartWare Is Premium-Priced Growth, But Could Still Go Higher

Just in recent memory, investors have had little problem with talking highly-valued med-tech stories like Edwards Lifesciences (NYSE:EW), Intuitive Surgical (NASDAQ:ISRG), and Cepheid (NASDAQ:CPHD) and pushing them even higher on their uncommonly strong revenue growth numbers. Along those same lines, I think HeartWare (NASDAQ:HTWR) could continue to head higher, despite an already rich valuation, on news of strong share/unit growth. That said, investors would do well to notice that the three aforementioned stocks have all had periods where the stock sold off pretty sharply (and pretty quickly), so HeartWare is not for the faint of heart.

Off To A Good Start

HeartWare recently reported results for the fourth quarter of 2012, the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details